Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs.

Hong H, Coutanceau E, Leclerc M, Caleechurn L, Leadlay PF, Demangel C.

PLoS Negl Trop Dis. 2008;2(10):e325. doi: 10.1371/journal.pntd.0000325. Epub 2008 Oct 22.

2.

Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring.

Sarfo FS, Le Chevalier F, Aka N, Phillips RO, Amoako Y, Boneca IG, Lenormand P, Dosso M, Wansbrough-Jones M, Veyron-Churlet R, Guenin-Macé L, Demangel C.

PLoS Negl Trop Dis. 2011 Jul;5(7):e1237. doi: 10.1371/journal.pntd.0001237. Epub 2011 Jul 19.

3.

Cellular immunity confers transient protection in experimental Buruli ulcer following BCG or mycolactone-negative Mycobacterium ulcerans vaccination.

Fraga AG, Martins TG, Torrado E, Huygen K, Portaels F, Silva MT, Castro AG, Pedrosa J.

PLoS One. 2012;7(3):e33406. doi: 10.1371/journal.pone.0033406. Epub 2012 Mar 8.

4.

Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone.

Coutanceau E, Decalf J, Martino A, Babon A, Winter N, Cole ST, Albert ML, Demangel C.

J Exp Med. 2007 Jun 11;204(6):1395-403. Epub 2007 May 21.

5.

Mycolactone gene expression is controlled by strong SigA-like promoters with utility in studies of Mycobacterium ulcerans and buruli ulcer.

Tobias NJ, Seemann T, Pidot SJ, Porter JL, Marsollier L, Marion E, Letournel F, Zakir T, Azuolas J, Wallace JR, Hong H, Davies JK, Howden BP, Johnson PD, Jenkin GA, Stinear TP.

PLoS Negl Trop Dis. 2009 Nov 24;3(11):e553. doi: 10.1371/journal.pntd.0000553. Erratum in: PLoS Negl Trop Dis. 2010;4(2). doi: 10.1371/annotation/1e664e6f-3fc8-4586-a84e-73c4ec4f783f.

6.

FVB/N Mice Spontaneously Heal Ulcerative Lesions Induced by Mycobacterium ulcerans and Switch M. ulcerans into a Low Mycolactone Producer.

Marion E, Jarry U, Cano C, Savary C, Beauvillain C, Robbe-Saule M, Preisser L, Altare F, Delneste Y, Jeannin P, Marsollier L.

J Immunol. 2016 Mar 15;196(6):2690-8. doi: 10.4049/jimmunol.1502194. Epub 2016 Feb 12.

7.

Detection of Mycolactone A/B in Mycobacterium ulcerans-Infected Human Tissue.

Sarfo FS, Phillips RO, Rangers B, Mahrous EA, Lee RE, Tarelli E, Asiedu KB, Small PL, Wansbrough-Jones MH.

PLoS Negl Trop Dis. 2010 Jan 5;4(1):e577. doi: 10.1371/journal.pntd.0000577.

8.

Mycolactone-mediated inhibition of tumor necrosis factor production by macrophages infected with Mycobacterium ulcerans has implications for the control of infection.

Torrado E, Adusumilli S, Fraga AG, Small PL, Castro AG, Pedrosa J.

Infect Immun. 2007 Aug;75(8):3979-88. Epub 2007 May 21.

9.

Interferon-γ Is a Crucial Activator of Early Host Immune Defense against Mycobacterium ulcerans Infection in Mice.

Bieri R, Bolz M, Ruf MT, Pluschke G.

PLoS Negl Trop Dis. 2016 Feb 10;10(2):e0004450. doi: 10.1371/journal.pntd.0004450. eCollection 2016 Feb.

10.

Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events.

Boulkroun S, Guenin-Macé L, Thoulouze MI, Monot M, Merckx A, Langsley G, Bismuth G, Di Bartolo V, Demangel C.

J Immunol. 2010 Feb 1;184(3):1436-44. doi: 10.4049/jimmunol.0902854. Epub 2009 Dec 30.

11.

Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease.

Phillips R, Sarfo FS, Guenin-Macé L, Decalf J, Wansbrough-Jones M, Albert ML, Demangel C.

J Infect Dis. 2009 Dec 1;200(11):1675-84. doi: 10.1086/646615.

PMID:
19863437
12.
13.

Chemistry of mycolactones, the causative toxins of Buruli ulcer.

Kishi Y.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6703-8. doi: 10.1073/pnas.1015252108. Epub 2011 Mar 7.

14.

Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.

Sarfo FS, Converse PJ, Almeida DV, Zhang J, Robinson C, Wansbrough-Jones M, Grosset JH.

PLoS Negl Trop Dis. 2013;7(3):e2101. doi: 10.1371/journal.pntd.0002101. Epub 2013 Mar 14.

15.

Vaccination with the Surface Proteins MUL_2232 and MUL_3720 of Mycobacterium ulcerans Induces Antibodies but Fails to Provide Protection against Buruli Ulcer.

Bolz M, Bénard A, Dreyer AM, Kerber S, Vettiger A, Oehlmann W, Singh M, Duthie MS, Pluschke G.

PLoS Negl Trop Dis. 2016 Feb 5;10(2):e0004431. doi: 10.1371/journal.pntd.0004431. eCollection 2016 Feb.

16.

Mycolactone is responsible for the painlessness of Mycobacterium ulcerans infection (buruli ulcer) in a murine study.

En J, Goto M, Nakanaga K, Higashi M, Ishii N, Saito H, Yonezawa S, Hamada H, Small PL.

Infect Immun. 2008 May;76(5):2002-7. doi: 10.1128/IAI.01588-07. Epub 2008 Mar 3.

17.

Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Fraga AG, Cruz A, Martins TG, Torrado E, Saraiva M, Pereira DR, Meyers WM, Portaels F, Silva MT, Castro AG, Pedrosa J.

Infect Immun. 2011 Jan;79(1):421-30. doi: 10.1128/IAI.00820-10. Epub 2010 Oct 25.

18.

Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection.

Walsh DS, Portaels F, Meyers WM.

Dermatol Clin. 2011 Jan;29(1):1-8. doi: 10.1016/j.det.2010.09.006. Review.

PMID:
21095521
19.

Buruli ulcer.

Einarsdottir T, Huygen K.

Hum Vaccin. 2011 Nov;7(11):1198-203. doi: 10.4161/hv.7.11.17751. Epub 2011 Nov 1. Review.

PMID:
22048117
20.

Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease.

Sarfo FS, Phillips RO, Zhang J, Abass MK, Abotsi J, Amoako YA, Adu-Sarkodie Y, Robinson C, Wansbrough-Jones MH.

BMC Infect Dis. 2014 Apr 15;14:202. doi: 10.1186/1471-2334-14-202.

Supplemental Content

Support Center